Literature DB >> 1688646

Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.

T D Meek1, D M Lambert, G B Dreyer, T J Carr, T A Tomaszek, M L Moore, J E Strickler, C Debouck, L J Hyland, T J Matthews.   

Abstract

The gag and pol genes of the human immunodeficiency virus type 1 (HIV-1) (ref. 1) are translated as two polyproteins, Pr55gag and Pr160gag-pol (refs 2-6), which are subsequently cleaved by the action of a virus-encoded protease into the four structural gag proteins of the virion core (p17, p24, p7 and p6) and the pol-encoded enzymes essential for retrovirus replication (protease, reverse transcriptase, ribonuclease H, and endonuclease). Mutational inactivation of the proteases of HIV-1 and other retroviruses results in immature, non-infectious virions, indicating that exogenous inhibition of the protease may represent an attractive approach to anti-AIDS therapy. Here we demonstrate that synthetic peptide analogues, which are potent inhibitors of purified HIV-1 protease, inhibit the processing of the viral polyproteins in cultures of HIV-1-infected T lymphocytes and attenuate viral infectivity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688646     DOI: 10.1038/343090a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  46 in total

1.  Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.

Authors:  D Xie; S Gulnik; E Gustchina; B Yu; W Shao; W Qoronfleh; A Nathan; J W Erickson
Journal:  Protein Sci       Date:  1999-08       Impact factor: 6.725

2.  Isolation of peptide aptamers that inhibit intracellular processes.

Authors:  J H Blum; S L Dove; A Hochschild; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

Review 3.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

4.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor.

Authors:  A L Swain; M M Miller; J Green; D H Rich; J Schneider; S B Kent; A Wlodawer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.

Authors:  A H Kaplan; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

6.  Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein.

Authors:  R J Tritch; Y E Cheng; F H Yin; S Erickson-Viitanen
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

Review 7.  Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes.

Authors:  W G Dougherty; B L Semler
Journal:  Microbiol Rev       Date:  1993-12

8.  In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.

Authors:  S Kageyama; T Mimoto; Y Murakawa; M Nomizu; H Ford; T Shirasaka; S Gulnik; J Erickson; K Takada; H Hayashi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 9.  The role of protease inhibitor therapy in children with HIV infection.

Authors:  Patrick J Gavin; Ram Yogev
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.

Authors:  X Wu; H Liu; H Xiao; J A Conway; J C Kappes
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.